Etanercept Use in the Management of Pediatric Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Case Report

Files

Authors

Rana Hegazi, Corewell Health West Resident
Emmy Grinstead, Corewell Health West Resident
Charlyne Cuyar Cruz, Corewell Health West Resident

Description

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immune-mediated, dermatologic emergencies associated with high morbidity and mortality. Current therapeutic guidelines involve discontinuing offending agents and management of symptoms with supportive care. Growing evidence suggests that the use of TNF-alpha inhibitors, such as etanercept, early in the disease course may improve patient outcomes by inhibiting disease progression. We present the case of a 14-year-old young man diagnosed with SJS/TEN, presumed to be triggered by a preceding viral infection vs Group A Strep pharyngitis.

Publication Date

5-9-2025

Disciplines

Pediatrics

Recommended Citation

Hegazi R, Grinstead E, Cuyar Cruz C. Etanercept use in the management of pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: a case report. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.

Comments

2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1853